The electrical activity of the retina in response to light stimuli is measured by a diagnostic procedure called an electroretinogram (ERG). Retinal degenerations, diabetic retinopathy, and hereditary retinal illnesses are just a few of the retinal problems and disorders that can be diagnosed using this test, which also helps evaluate the function of the retina, especially the photoreceptor cells. The process involves stimulating the retina with light flashes while electrodes are applied to the surface of the eye or the skin surrounding the eyes. The retina's health and function are assessed by recording and analyzing the electrical impulses it produces in response to light. ERGs offer important information about retinal health and aid in treatment planning, making them useful instruments in both clinical and research contexts.

Market Drivers: The demand for electroretinograms (ERG) is being driven by the growing number of ophthalmology clinics and research institutions as well as the increasing prevalence of eye disorders. The market is anticipated to expand because to conditions like retinitis pigmentosa, macular degeneration, glaucoma, and diabetic retinopathy. This tendency is also influenced by an aging population, increased screen time during the epidemic, and an increasing preference for early detection. ERGs are crucial for the diagnosis of retinitis pigmentosa, macular degeneration, and retinal detachment because they quantify the retina's electrical response to light stimuli. Millions of elderly persons have been diagnosed with diabetic retinopathy, a leading cause of blindness. ERGs' use in diagnosis will raise their demand in the ophthalmology market as more people become aware of these disorders. 

Challenges:  One major barrier to market expansion is the high cost of electroretinography (ERG) equipment. It is expected that this will restrict access to diagnostic services. Because ERG equipment, particularly sophisticated versions, can be costly, small clinics, hospitals, and healthcare professionals in low-resource environments may find it difficult to make the investment.

The cost barrier prevents ERG testing from being widely used, especially in developing nations where more economical options are required. Insurance coverage is also impacted by the cost aspect, which could prevent patients from receiving the required retinal exams. Therefore, even though ERG is an important diagnostic tool, its expensive cost may prevent it from being widely accessible and used in normal eye care.

By Region: North America dominated the global electroretinogram market in 2024, owing to a growing older population, rising prevalence of eye problems, higher approvals and investments in R&D, and a strong tendency for adopting innovative products in the United States. Furthermore, hospital expansion, together with the availability of a strong healthcare infrastructure and research institutions, is predicted to considerably contribute to the North American market's continuing growth.

Allison Medical, BioRad Laboratories, Diagnosys LLC, HEINE Optotechnik, Konan Medical, LKC Technologies, Marco Ophthalmic, Metrovision, Nidek, Topcon Healthcare, Others.

By Type: Based on the Type, Global Electroretinogram Market is segmented as; Full-field flash ERG (ffERG), Pattern ERG (PERG), Multifocal ERG (mfERG)

By Product: Based on the Product, Global Electroretinogram Market is segmented as; Handheld, Tabletop.

By Application: Based on the Application, Global Electroretinogram Market is segmented as; Clinical Diagnostic, Research.

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.